224 related articles for article (PubMed ID: 9673264)
61. Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens.
McGuirk P; Johnson PA; Ryan EJ; Mills KH
J Infect Dis; 2000 Oct; 182(4):1286-9. PubMed ID: 10979938
[No Abstract] [Full Text] [Related]
62. Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin.
Ishibashi Y; Nishikawa A
Microb Pathog; 2002 Sep; 33(3):115-25. PubMed ID: 12220988
[TBL] [Abstract][Full Text] [Related]
63. Pertussis seroepidemiology in Taipei.
Chiu TF; Lee CY; Lee PI; Lu CY; Lin HC; Huang LM
J Formos Med Assoc; 2000 Mar; 99(3):224-8. PubMed ID: 10820955
[TBL] [Abstract][Full Text] [Related]
64. Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth.
Wood N; Marshall H; White OJ; Holt PG; McIntyre P
Pediatr Infect Dis J; 2014 May; 33(5):511-7. PubMed ID: 24445839
[TBL] [Abstract][Full Text] [Related]
65. Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
Watanabe M; Funaishi K; Takeo T; Endoh M
Vaccine; 2000 Dec; 19(9-10):1204-10. PubMed ID: 11137258
[TBL] [Abstract][Full Text] [Related]
66. A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.
Berbers GA; van de Wetering MS; van Gageldonk PG; Schellekens JF; Versteegh FG; Teunis PF
Vaccine; 2013 Aug; 31(36):3732-8. PubMed ID: 23742995
[TBL] [Abstract][Full Text] [Related]
67. Dissecting human T cell responses against Bordetella species.
De Magistris MT; Romano M; Nuti S; Rappuoli R; Tagliabue A
J Exp Med; 1988 Oct; 168(4):1351-62. PubMed ID: 2902185
[TBL] [Abstract][Full Text] [Related]
68. Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutinin.
Dirix V; Mielcarek N; Debrie AS; Willery E; Alonso S; Versheure V; Mascart F; Locht C
Microbes Infect; 2014 Jul; 16(7):562-70. PubMed ID: 24801497
[TBL] [Abstract][Full Text] [Related]
69. Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
Khelef N; Danve B; Quentin-Millet MJ; Guiso N
Infect Immun; 1993 Feb; 61(2):486-90. PubMed ID: 8423077
[TBL] [Abstract][Full Text] [Related]
70. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
[TBL] [Abstract][Full Text] [Related]
71. Pertussis antigens that abrogate bacterial adherence and elicit immunity.
Brennan MJ; Shahin RD
Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 2):S145-9. PubMed ID: 8876533
[TBL] [Abstract][Full Text] [Related]
72. Antigenic analysis of Bordetella pertussis filamentous hemagglutinin with phage display libraries and rabbit anti-filamentous hemagglutinin polyclonal antibodies.
Wilson DR; Siebers A; Finlay BB
Infect Immun; 1998 Oct; 66(10):4884-94. PubMed ID: 9746593
[TBL] [Abstract][Full Text] [Related]
73. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
Ausiello CM; Lande R; Urbani F; Di Carlo B; Stefanelli P; Salmaso S; Mastrantonio P; Cassone A
J Infect Dis; 2000 Jun; 181(6):1989-95. PubMed ID: 10837180
[TBL] [Abstract][Full Text] [Related]
74. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
[TBL] [Abstract][Full Text] [Related]
75. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis.
Isacson J; Trollfors B; Taranger J; Lagergård T
Pediatr Infect Dis J; 1995 Jun; 14(6):517-21. PubMed ID: 7667057
[TBL] [Abstract][Full Text] [Related]
76. Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.
García-Corbeira P; Dal-Ré R; Aguilar L; García-de-Lomas J
Vaccine; 2000 Apr; 18(21):2173-6. PubMed ID: 10717335
[TBL] [Abstract][Full Text] [Related]
77. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents after a whole cell (wcP) or aP primary vaccination.
Prelog M; Almanzar G; Rieber N; Ottensmeier B; Zlamy M; Liese J
Vaccine; 2013 Jan; 31(2):387-93. PubMed ID: 23142306
[TBL] [Abstract][Full Text] [Related]
78. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.
Zepp F; Knuf M; Habermehl P; Schmitt JH; Rebsch C; Schmidtke P; Clemens R; Slaoui M
Infect Immun; 1996 Oct; 64(10):4078-84. PubMed ID: 8926072
[TBL] [Abstract][Full Text] [Related]
79. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
Berstad AK; Oftung F; Korsvold GE; Haugen IL; Froholm LO; Holst J; Haneberg B
Vaccine; 2000 May; 18(22):2323-30. PubMed ID: 10738087
[TBL] [Abstract][Full Text] [Related]
80. Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.
Mielcarek N; Nordström I; Menozzi FD; Locht C; Holmgren J
Infect Immun; 2000 Feb; 68(2):485-91. PubMed ID: 10639408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
